Related references
Note: Only part of the references are listed.Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
Gerald Raverot et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
Ann I. McCormack et al.
CLINICAL ENDOCRINOLOGY (2009)
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
C. Hagen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
A novel use of temozolomide in a patient with malignant prolactinoma
Stephen Byrne et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas?
Mustafa Khasraw et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
New (alternative) temozolomide regimens for the treatment of glioma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2009)
USE OF TEMOZOLOMIDE IN AGGRESSIVE PITUITARY TUMORS: CASE REPORT
Safraz Mohammed et al.
NEUROSURGERY (2009)
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
A. Tosoni et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
Thierry Gorlia et al.
LANCET ONCOLOGY (2008)
Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
Jonathon F. Parkinson et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
Kalman Kovacs et al.
ACTA NEUROPATHOLOGICA (2008)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists
Lisa M. Neff et al.
PITUITARY (2007)
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings
Kalman Kovacs et al.
HUMAN PATHOLOGY (2007)
Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm
Luis V. Syro et al.
CLINICAL ENDOCRINOLOGY (2006)
Long-term response of pituitary carcinoma to temozolomide - Report of two cases
Camilo E. Fadul et al.
JOURNAL OF NEUROSURGERY (2006)
Clinical review: Diagnosis and management of pituitary carcinomas
GA Kaltsas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
MGMT: Its role in cancer aetiology and cancer therapeutics
SL Gerson
NATURE REVIEWS CANCER (2004)
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors
NM Lindor et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors - Comparison between micro- and macroadenomas
M Losa et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
